Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px
Document › Details

Boehringer Ingelheim. (6/22/18). "Press Release: Boehringer Ingelheim Bolsters Biologics Research and Development with 230 Million Euro Investment in New Development Center". Biberach.

Region Region Biberach/Riß
  Country Germany
Organisations Organisation Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach
  Group Boehringer Ingelheim (Group)
  Organisation 2 Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd.
  Group Boehringer Ingelheim (Group)
Products Product contract manufacturing (biologicals)
  Product 2 biopharmaceutical
Persons Person Traulsen, Fridtjof (Boehringer Ingelheim 201806 Corporate SVP Development)
  Person 2 Malin, Reinhard (Boehringer Ingelheim 201505 Director Media + PR)
     


> New Biologicals Development Center in Biberach, Germany bundles biologics development, increases capacity and expands clinical supply network

> Increased development capacities reflect research pipeline growth and free up capacity for contract manufacturing

> Focus on therapeutic areas with high unmet medical need such as cancer and immunological diseases


Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center.

“The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.”

The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning in 2020, the new building will be home to 500 employees. This is an increase of about 100 employees in biologicals development compared to today.

The new BDC adds to a number of major recent investments into the global Boehringer Ingelheim biopharmaceuticals development network aiming to further increase the company’s mammalian cell culture capabilities in this important area, including the large scale biopharmaceuticals facility in Vienna, Austria, a new biopharmaceuticals facility in Shanghai, China, and the expansion of existing large scale biopharmaceutical capacities in Fremont, CA, USA, leading to an overall increase of investment in biopharmaceutical research, development and production.

Boehringer Ingelheim has developed biopharmaceuticals, such as a humanized antibody fragment that selectively reverts the effect of an oral anticoagulant prior to urgent procedures / emergency surgery or in uncontrolled bleeding, a first-in-class Interleukin-36 receptor antibody is being tested among others for special forms of psoriasis (generalized pustular psoriasis and palmoplantar pustulosis) as well as ulcerative colitis and crohn’s disease and several antibodies under investigation for difficult to treat cancers. Boehringer Ingelheim is committing more than 20% of its human pharma net sales to Research & Development. More than 8,000 employees work in four R&D centers of excellence on a highly innovative pipeline, 50% of which is anchored in external innovation.

Boehringer Ingelheim BioXcellence™ is a leader in biopharmaceutical contract manufacturing for large volume products, manufacturing 29 biopharmaceuticals for industry partners from around the world. These include monoclonal antibodies for oncology and immunology, interferons and other targeted therapies.


Intended audiences

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.


About Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com, in our annual report on http://annualreport.boehringer-ingelheim.com and http://www.bioxcellence.com


Media Contact

Dr Reinhard Malin

Media Contact - Innovation Unit
Media & PR
Phone +49 6132 77 90815
Mobile +49 151 150 20690
Fax +49 6132 77 6601

› E-mail › Add Contact

Binger Strasse 173
55216 Ingelheim am Rhein
GERMANY

   
Record changed: 2018-06-29

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for Boehringer Ingelheim (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px




» top